|
시장보고서
상품코드
2089702
장기지속형 주사제 시장 규모, 점유율 및 동향 분석 보고서 : 치료 영역별, 분자 유형별, 투여 경로별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)Long-acting Injectables Therapeutics Market Size, Share & Trends Analysis Report By Therapeutic Area, By Molecule Type, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
장기지속형 주사제 시장 개요
세계의 장기지속형 주사제 치료제 시장 규모는 2025년에 183억 달러로 평가되며, 2026-2033년에 CAGR 12.8%로 확대하며, 2033년까지 205억 달러에서 477억 달러에 달할 것으로 예측됩니다.
2025년에는 북미가 세계 시장의 41.8%를 차지하며 가장 큰 점유율을 기록했습니다. 만성질환 및 복합 질환에 대한 서방형 치료법에 대한 수요가 증가함에 따라 LAI(장시간 작용형 주사제) 시장은 첨단 약물전달 시스템 중에서도 중요한 부문으로 발전하고 있습니다.
초기에는 정신 질환, 특히 조현병 치료에 중점을 두었으나, LAI는 환자의 복약 순응도를 높이고 투여 빈도를 줄이는 폭넓은 치료 접근법으로서 점차 주목을 받기 시작했습니다.
이러한 변화는 임상적 유효성은 물론, 치료의 편의성과 장기적인 질환 관리가 우선시되는 환자 중심의 치료 모델로 나아가려는 업계 전반의 추세를 반영하고 있습니다. 의료제도가 성과 중심의 치료를 지속적으로 강조하는 가운데, LAI는 복약 순응도 저하 문제를 해결하고 치료의 지속성을 전반적으로 향상시키기 위한 전략적 해결책으로서 점점 더 널리 인정받고 있습니다.
업계에서는 기존의 정신과 분야를 넘어 대대적인 확장이 진행되고 있으며, 감염증, 종양학의 보조 요법, 호르몬 요법 등에서 그 활용이 확대되고 있습니다. 마이크로스피어 제제, 생분해성 서방형 제제, 지속형 바이오의약품 등의 약물전달 기술의 발전으로 인해 투여 간격을 수 주에서 수 개월까지 연장할 수 있게 되었습니다. 이러한 기술적 진보는 약동학 프로파일의 개선과 치료 부담 경감을 실현하는 차세대 치료법의 개발을 촉진하고 있습니다. 각 제약사는 파이프라인 확충과 제형 혁신에 적극적으로 투자하고 있으며, 이는 LAI가 세계 헬스케어 시장에서 임상적·상업적 중요성이 높아지고 있는 다중 치료 영역에 걸친 플랫폼으로 전환되는 데 기여하고 있습니다.
LAI 치료제 업계는 연구개발 투자 증가, 전략적 제휴, 그리고 주사제 수명 주기 관리에 대한 중요성 증대를 특징으로 하고 있습니다. 이러한 치료법은 비용이 높기 때문에 가격 책정 및 보험 급여와 관련된 과제가 여전히 중요한 고려 사항으로 남아 있지만, 입원율 감소와 환자 예후 개선을 통해 그 가치 제안은 더욱 강화되고 있습니다. 또한 장기 작용형 제제에 대한 임상적 근거가 확대되고 규제 당국의 관심이 높아지면서 시장이 활성화되고 있으며, LAI는 향후 약물전달 전략에서 중요한 구성 요소로서의 입지를 확립해 가고 있습니다. 전반적으로 혁신, 치료법의 다양화, 그리고 복약 순응도에 중점을 둔 치료 솔루션에 대한 전 세계적인 수요 증가에 힘입어 시장은 지속적인 성장세를 보이고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 장기지속형 주사제 시장 : 변수, 동향, 범위
제4장 장기지속형 주사제 시장 : 치료 영역별 비즈니스 분석
제5장 장기지속형 주사제 시장 : 분자 유형별 비즈니스 분석
제6장 장기지속형 주사제 시장 : 투여 경로별 비즈니스 분석
제7장 장기지속형 주사제 시장 : 유통 채널별 비즈니스 분석
제8장 장기지속형 주사제 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSA 26.07.20Long-acting Injectables Therapeutics Market Summary
The global long-acting injectables therapeutics market size was valued at USD 18.3 billion in 2025 and is projected to grow from USD 20.5 billion to USD 47.7 billion by 2033, at a CAGR of 12.8% from 2026 to 2033. North America held the largest share of 41.8% of the global market in 2025. The LAI therapeutics market is evolving into a prominent segment within advanced drug delivery systems, driven by the growing need for sustained-release treatment options across chronic and complex diseases.
Initially concentrated in the management of psychiatric disorders, particularly schizophrenia, LAIs have progressively gained traction as a broader therapeutic approach that enhances patient adherence and reduces the frequency of dosing.
This shift reflects a wider industry movement toward patient-centric care models, where treatment convenience and long-term disease control are prioritized alongside clinical efficacy. As healthcare systems continue to emphasize outcomes-based care, LAIs are increasingly being recognized as a strategic solution to address medication non-compliance and improve overall treatment continuity.
The industry is experiencing significant expansion beyond its traditional psychiatric applications, with growing adoption in infectious diseases, oncology support therapies, and hormonal treatments. Advancements in drug delivery technologies, including microsphere-based formulations, biodegradable depots, and long-acting biologics, are enabling extended dosing intervals ranging from weeks to several months. This technological progress is facilitating the development of next-generation therapies that offer improved pharmacokinetic profiles and reduced treatment burden. Pharmaceutical companies are actively investing in pipeline expansion and formulation innovation, supporting the transition of LAIs into a multi-therapeutic platform with increasing clinical and commercial relevance across global healthcare markets.
The LAI therapeutics industry is characterized by rising investments in research and development, strategic collaborations, and growing emphasis on lifecycle management of injectable products. While pricing and reimbursement challenges remain key considerations due to the premium nature of these therapies, their value proposition is strengthened by reduced hospitalization rates and improved patient outcomes. The market is further supported by expanding clinical evidence and regulatory interest in long-acting formulations, positioning LAIs as a critical component of future drug delivery strategies. Overall, the market is moving toward sustained growth, underpinned by innovation, therapeutic diversification, and increasing global demand for adherence-focused treatment solutions.
Global Long-acting Injectables Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global long-acting injectables therapeutics market report based on therapeutic area, molecule type, route of administration, distribution channel, and region:
- Therapeutic Area Outlook (Revenue, USD Billion, 2021 - 2033)
- Central Nervous System (CNS) Disorders
- Infectious Diseases
- Metabolic & Endocrine Disorders
- Oncology
- Autoimmune & Inflammatory Diseases
- Other Therapeutic Areas
- Molecule Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Small Molecules
- Biologics
- Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
- Intramuscular (IM)
- Subcutaneous (SC)
- Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospital Pharmacies
- Specialty Pharmacies
- Retail Pharmacies
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Therapeutic Area
- 1.2.2. Molecule Type
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Long-acting Injectables Therapeutics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Long-acting Injectables Therapeutics Market: Therapeutic Area Business Analysis
- 4.1. Therapeutic Area Market Share, 2025 & 2033
- 4.2. Therapeutic Area Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Billion)
- 4.4. Central Nervous System (CNS) Disorders
- 4.4.1. Central Nervous System (CNS) Disorders Market, 2021 - 2033 (USD Billion)
- 4.5. Infectious Diseases
- 4.5.1. Infectious Diseases Market, 2021 - 2033 (USD Billion)
- 4.6. Metabolic & Endocrine Disorders
- 4.6.1. Metabolic & Endocrine Disorders Market, 2021 - 2033 (USD Billion)
- 4.7. Oncology
- 4.7.1. Oncology Market, 2021 - 2033 (USD Billion)
- 4.8. Autoimmune & Inflammatory Diseases
- 4.8.1. Autoimmune & Inflammatory Diseases Market, 2021 - 2033 (USD Billion)
- 4.9. Other Therapeutic Areas
- 4.9.1. Other Therapeutic Areas Market, 2021 - 2033 (USD Billion)
Chapter 5. Long-acting Injectables Therapeutics Market: Molecule Type Business Analysis
- 5.1. Molecule Type Market Share, 2025 & 2033
- 5.2. Molecule Type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Molecule Type, 2021 to 2033 (USD Billion)
- 5.4. Small Molecules
- 5.4.1. Small Molecules Market, 2021 - 2033 (USD Billion)
- 5.5. Biologics
- 5.5.1. Biologics Market, 2021 - 2033 (USD Billion)
Chapter 6. Long-acting Injectables Therapeutics Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2025 & 2033
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
- 6.4. Intramuscular (IM)
- 6.4.1. Intramuscular (IM) Market, 2021 - 2033 (USD Billion)
- 6.5. Subcutaneous (SC)
- 6.5.1. Subcutaneous (SC) Market, 2021 - 2033 (USD Billion)
Chapter 7. Long-acting Injectables Therapeutics Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2025 & 2033
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Billion)
- 7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.5. Specialty Pharmacies
- 7.5.1. Specialty Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.6. Retail Pharmacies
- 7.6.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
Chapter 8. Long-acting Injectables Therapeutics Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 8.4. North America
- 8.4.1. North America Long-acting Injectables Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Framework
- 8.4.2.5. U.S. Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Framework
- 8.4.3.5. Canada Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Framework
- 8.4.4.5. Mexico Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5. Europe
- 8.5.1. Europe Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Framework
- 8.5.2.5. UK Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Framework
- 8.5.3.5. Germany Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Framework
- 8.5.4.5. France Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Target Disease Prevalence
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Framework
- 8.5.5.5. Italy Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Target Disease Prevalence
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Reimbursement Framework
- 8.5.6.5. Spain Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Target Disease Prevalence
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement Framework
- 8.5.7.5. Denmark Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Target Disease Prevalence
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Reimbursement Framework
- 8.5.8.5. Sweden Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Target Disease Prevalence
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Reimbursement Framework
- 8.5.9.5. Norway Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Framework
- 8.6.2.5. Japan Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Framework
- 8.6.3.5. China Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement Framework
- 8.6.4.5. India Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement Framework
- 8.6.5.5. Australia Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Target Disease Prevalence
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Reimbursement Framework
- 8.6.6.5. South Korea Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Target Disease Prevalence
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Reimbursement Framework
- 8.6.7.5. Thailand Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7. Latin America
- 8.7.1. Latin America Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Target Disease Prevalence
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Framework
- 8.7.2.5. Brazil Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Target Disease Prevalence
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Framework
- 8.7.3.5. Argentina Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Target Disease Prevalence
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Reimbursement Framework
- 8.8.2.5. South Africa Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Target Disease Prevalence
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Reimbursement Framework
- 8.8.3.5. Saudi Arabia Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Target Disease Prevalence
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Reimbursement Framework
- 8.8.4.5. UAE Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Target Disease Prevalence
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Reimbursement Framework
- 8.8.5.5. Kuwait Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. Johnson & Johnson
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. Gilead Sciences
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Eli Lilly and Company
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. AstraZeneca
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Otsuka Pharmaceutical
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. Lundbeck
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. Pfizer
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. Takeda Pharmaceutical Company
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. Novartis AG
- 9.5.9.1. Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Product Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.1. Johnson & Johnson
